Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ANTARES PHARMA, INC. (ATRS)
|
Add to portfolio |
|
|
|
| Price: |
$3.57
| | Metrics |
| OS: |
170.9
|
M
| |
|
|
| Market cap: |
$610
|
M
| |
|
|
|
Net cash:
|
$42.8
|
M
| |
$0.25
|
per share
|
|
EV:
|
$567
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
$63.4
|
M
| |
8.9
|
x EV/EBIT
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 184.0 | 149.6 | 123.9 | 63.6 | 54.5 | 52.2 | 45.7 | 26.5 |
| Revenue growth | 23.0% | 20.8% | 94.9% | 16.6% | 4.4% | 14.4% | 72.3% | 28.5% |
| Cost of goods sold | 29.7 | 63.1 | 50.5 | 18.6 | 27.5 | 28.8 | 19.5 | 11.2 |
| Gross profit | 154.3 | 86.5 | 73.4 | 45.0 | 27.0 | 23.4 | 26.2 | 15.3 |
| Gross margin | 83.9% | 57.8% | 59.2% | 70.8% | 49.6% | 44.8% | 57.4% | 57.6% |
| Selling, general and administrative | 73.9 | 62.8 | 61.8 | 36.8 | 31.6 | 27.9 | 26.9 | 31.7 |
| Research and development | 14.5 | 10.1 | 10.6 | 12.3 | 11.9 | 19.6 | 19.7 | 18.6 |
| EBITA | 104.5 | 13.6 | 1.0 | 8.4 | -14.7 | -24.1 | -20.4 | -35.1 |
| EBITA margin | 56.8% | 9.1% | 0.8% | 13.2% | -27.0% | -46.2% | -44.7% | -132.5% |
| Amortization of intangibles | | | | | | | 0.0 | |
| EBIT | 104.5 | 13.6 | 1.0 | 8.4 | -14.7 | -24.1 | -20.5 | -35.1 |
| EBIT margin | 56.8% | 9.1% | 0.8% | 13.2% | -27.0% | -46.2% | -44.8% | -132.5% |
| Pre-tax income | 62.3 | 9.9 | -2.0 | -6.5 | -16.7 | -24.2 | -20.5 | -35.1 |
| Income taxes | 16.0 | -46.3 | 0.0 | 0.0 | 0.0 | 0.1 | 0.2 | 0.0 |
| Tax rate | 25.7% | | 0.0% | 0.0% | 0.0% | | | |
| Net income | 46.3 | 56.2 | -2.0 | -6.5 | -16.7 | -24.3 | -20.7 | -35.2 |
| Net margin | 25.2% | 37.6% | -1.6% | -10.3% | -30.7% | -46.6% | -45.2% | -132.6% |
| |
| Diluted EPS | $0.26 | $0.33 | ($0.01) | ($0.04) | ($0.11) | ($0.16) | ($0.14) | ($0.27) |
| Shares outstanding (diluted) | 174.7 | 170.2 | 162.6 | 157.4 | 156.1 | 155.0 | 146.6 | 130.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|